The U.S. Food and Drug Administration and the Department of Health and Human Services announced coordinated enforcement actions against Hims & Hers Health’s compounded GLP‑1 weight‑loss products, a move that could reshape the company’s most profitable segment.
The crackdown centers on the use of GLP‑1 active pharmaceutical ingredients in non‑FDA‑approved compounded formulations. Hims & Hers had previously received a warning letter in September 2025 for misleading advertising that implied its compounded semaglutide was equivalent to FDA‑approved drugs. The new actions signal a broader regulatory push to curb mass‑marketed compounding of GLP‑1 therapies, which the agencies say lack the safety and quality oversight of approved products.
Financially, the GLP‑1 business accounts for roughly one‑third of Hims & Hers’ $599 million revenue in Q3 2025, and the company reported a 49% year‑over‑year revenue increase that quarter. Gross margin fell from 79% in Q3 2024 to 74% in Q3 2025, reflecting pricing pressure and higher cost of raw materials as the company scales its compounding operations. The regulatory threat could further compress margins if product restrictions or fines are imposed.
Management has emphasized its commitment to safety and compliance, stating that the company will “continue to work closely with regulators to ensure all products meet the highest standards.” The company’s spokesperson also noted that it is exploring alternative revenue streams, including expanding its telehealth platform and developing proprietary formulations that meet FDA approval requirements.
Investors have reacted negatively to the announcement, citing the potential for enforcement actions, product restrictions, and fines that could erode the GLP‑1 revenue stream and increase compliance costs. The regulatory action underscores the growing scrutiny of compounded biologics and signals a shift toward stricter oversight of off‑label drug use.
The move places Hims & Hers in a precarious position: while its overall platform has driven strong growth, the company’s reliance on a single, high‑margin product line now faces significant regulatory risk that could alter its competitive dynamics and financial trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.